PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc. (OAPI) and Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has expanded the label of ...
The majority of the 70 primary studies (comprising 2,163 patients) were conducted in Europe (n = 35) or North America (n = 18), while nine studies were completed in Asia and eight in other geographic ...
TITUSVILLE, N.J., Oct. 9 /PRNewswire-FirstCall/ -- Patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ([risperidone] Long ...
TITUSVILLE, N.J., Oct. 9 Patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ([risperidone] Long-Acting Injection). The U.S. Food and Drug Administration (FDA) ...
The start of any new gene therapy trial is an exciting and nervous time. But for the participants and doctors involved in the recently launched trial for Duchenne Muscular Dystrophy (DMD) at Columbus ...
Revance Therapeutics Inc (NASDAQ: RVNC) has reported topline data from JUNIPER Phase 2 study evaluating DaxibotulinumtoxinA for Injection to treat adults with moderate to severe upper limb spasticity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results